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Abstract  
Background: Gastrointestinal involvement in systemic sclerosis is common and a major cause of disease-
related morbidity.  Patients increasingly enquire about dietary modifications that may help with 
gastrointestinal symptoms and many clinical practice reviews and treatment guidelines make specific 
reference to dietary modifications in the management of gastrointestinal involvement in systemic 
sclerosis. We report the findings of a systematic literature review designed to evaluate the evidence to 
support dietary modification in the management of gastrointestinal symptoms of systemic sclerosis.  
Methods: A systematic literature review protocol was developed according to Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses guidelines and registered with the International prospective 
register of systematic reviews (CRD42018103549). Standardised searches of EMBASE and MEDLINE were 
undertaken to identify studies reporting the outcome of dietary modification in the management of 
gastrointestinal symptoms of systemic sclerosis. Wide heterogeneity in study design, interventions and 
study outcomes necessitated a qualitative data synthesis. 
Results: Our standardised searches identified 1032 articles, of which 3 were deemed eligible for full data 
extraction. These studies were small (mean 19 subjects per study), single centre, short-term (mean 6 
week duration) open-label non-randomised studies examining the role of probiotics, low-fermentable 
oligo-saccharides, disaccharides, monosaccharides, and polyol (low-FODMAP) diet and highly 
individualised medical nutrition therapy counselling respectively. Improvements in patient-reported 
outcome assessment of gastrointestinal symptoms were reported after intervention with probiotic 
therapy and low-FODMAP diet but not following tailored dietary and nutritional counselling. The Risk of 
Bias Assessment Tool for Nonrandomized Studies identified high risk-of-bias for confounding variables 
and blinding of assessors in each of the three studies evaluated. 
Conclusions: The evidence-base to support dietary modification for gastrointestinal involvement in 
systemic sclerosis is currently limited and clinical practice guidelines should take a measured approach to 
such recommendations. The recent emergence of large patient registries could facilitate the capture vital 
practice-based evidence regarding the efficacy of dietary modification in the management of 
gastrointestinal involvement in systemic sclerosis to inform future clinical practice guidelines.  
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Introduction 
Systemic sclerosis (SSc) is a multisystem autoimmune disease characterised by aberrant tissue 
remodelling with fibrosis occurring in multiple organs including the skin, lungs and gastrointestinal (GI) 
tract [1]. Fibrosis and smooth muscle atrophy within the GI tract results in sphincter disturbance (gastro-
oesophageal reflux disease, GORD and ano-rectal dysfunction) and delayed GI transit (dysphagia, 
gastroparesis, small intestinal bacterial overgrowth, constipation). GI symptoms of SSc are very common 
and a major cause of disease-related morbidity [2-4]. A number of reviews and clinical practice 
guidelines stress the importance of dietary and lifestyle modifications in managing GI disease. These 
range from supplemental calories, alteration of fibre intake, probiotics, vitamin supplementation or 
changes to the timing, frequency, size or composition (exclusion and inclusion of particular food stuffs) 
of meals [5-7]. Many patients make enquires to their healthcare practitioners about dietary 
modifications that might help them symptomatically. Interest in this field has been bolstered by recent 
work that has identified characteristic intestinal microbiome signatures in SSc.  Speculation has 
mounted concerning the potential role of dietary modification and probiotics to modify the GI tract 
microbiota in an attempt to improve GI symptoms and augment pathological drivers of the disease [8].  
The principal objective of this systematic literature review is to identify and critically appraise the 
current evidence concerning the efficacy of dietary modifications on GI symptoms in SSc. Where 
applicable, limitations of existing research and knowledge gaps shall be highlighted alongside 
suggestions for future research.  
METHODS AND ANALYSIS 
Protocol development and review registration 
A study protocol was developed according to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA-P) guidelines [9] and registered in the International Prospective Register of 
Systematic Reviews (Registration: PROSPERO CRD42018103549).  
Eligibility criteria 
Studies reporting the impact of dietary intervention (of any form) on gastrointestinal symptoms in SSc 
were included in this systematic literature review. Applying the PICOS framework, we sought to evaluate 
publications that fulfilled the following study characteristics: 
Participants: Adults (18 years or older) with a diagnosis of SSc 
Intervention: Studies reporting the outcome of dietary intervention for GI symptoms of SSc. All dietary 
and lifestyle interventions for managing GI symptoms (e.g. advice on size, timing and frequency of 
meals, vitamin supplementation, exclusionary diets, probiotic use, antioxidants, etc.) were included. We 
didn’t include assessment of non-dietary parenteral interventions. 
Comparison: Where applicable, comparison shall be made with outcomes in active treatment arms 
versus control groups. Uncontrolled open-label interventions were also eligible providing they reported 
GI symptoms/physiological studies at baseline and following dietary modification. 
Outcomes: The primary objective is to evaluate the clinical value of dietary interventions in managing GI 
symptoms of SSc. All methods for reporting change in GI disease including symptoms (from mouth to 
anus) and surrogates of GI dysfunction (such as GI physiology and/or imaging) before and after dietary 
modification were eligible for inclusion. Studies examining nutritional status (e.g. BMI, nutrition scores) 
as a solitary endpoint were not included.  
Study design: Longitudinal studies reporting an assessment of the efficacy/impact of dietary modification 
(of any description) on GI manifestations of SSc were eligible for inclusion. All applicable study 
methodology (open-label, controlled, randomised, prospective, retrospective etc.) were eligible for 
inclusion. The following studies were excluded from the analysis; pre-clinical/animal studies, studies of 
childhood/juvenile SSc, studies of mixed patient populations (e.g. primary Raynaud’s phenomenon, 
undifferentiated connective tissue diseases or overlap syndromes) in which a SSc cohort was not 
adequately reported, studies designed to develop/validate measurement scales, case reports, qualitative 
research, non-original research publications (i.e., editorials, reviews), abbreviated reports (e.g. letters to 
editors), conference proceedings and non-English language publications. Details of the grounds for article 
exclusion were captured during study selection. 
Information sources and search criteria 
Electronic searches were undertaken in Medline and EMBASE databases using search criteria piloted 
during the planning phase. No publication date or language restrictions were applied to the searches. 
The following search criteria were developed and applied in both databases to capture articles relevant 
to the scope of this review: 
((systemic sclerosis) OR (CREST) OR (scleroderma)) AND (diet* OR fibre OR fiber OR supplements OR 
probiotics OR anti-oxidants OR vitamins OR meal OR nutrition OR eating OR food) AND (gastrointestinal 
OR intest* OR GI OR abdominal OR bloating OR nausea OR reflux OR diarrhoea OR constipation OR 
faec*)  
Study selection  
All titles and abstracts generated by the search were screened independently by two review authors (JP 
and LS) for relevance and eligibility of studies for full text review (See appendix 1). Cohen’s Kappa statistics 
were used to assess agreement between reviewers for articles considered relevant for full text review 
during the study selection process. Any divergence in agreement was resolved through discussion at each 
step of the study selection process. A “grey search” of potentially relevant articles cited on review of full 
text manuscripts was undertaken.  
Data extraction from selected studies 
Data was independently extracted by both reviewers (JDP and LS) using a standardized form piloted during 
protocol development (Appendix 2). The data extraction form collated relevant study details including 
date of publication, country of origin, intervention, study design, initial population of the study, study 
attrition, eligibility criteria, endpoints, adverse events, study attrition and a summary of key findings. Plans 
were in place to contact study authors should additional clarification be required. 
Risk of Bias Assessment 
Risk of bias within randomised and non-randomised controlled trials was assessed by both reviewers (LS 
and JP together) using the Cochrane Risk of Bias Assessment Tool for Randomised Trials or the Risk of Bias 
Assessment Tool for Nonrandomized Studies (RoBANS), as appropriate. Each tool assesses bias across the 
domains relating to patient selection, performance, detection, attrition and reporting [10, 11] (see 
Appendix 3).  Eligible studies were rated as high, low, or unclear (risk of bias), on each of these dimensions, 
culminating in an overall risk of bias (high/moderate/low).  
Strategy for data synthesis 
A qualitative data synthesis of the study findings was anticipated due to an expected high degree of study 
heterogeneity in terms of study design, intervention and outcome reporting; rendering any meaningful 
attempt at meta-analysis impossible.  
Results 
Study selection 
Searches of EMBASE (708 articles) and Medline (324 articles) were undertaken on 13th July 2018 
identifying a total of 1032 articles. After removal of duplications (n=141), the remaining 891 articles were 
screened for eligibility during a title and abstract review undertaken by both reviewers. A total of 8 studies 
fulfilled inclusion criteria but excluded on other grounds (5 conference abstracts and 3 case reports/series, 
Figure 1). There was good agreement between the reviewers (Kappa 0.726) for studies eligibility for full 
text review. Four studies were identified by both reviewers for full text analysis after title and abstract 
review. There was discordance as to whether 3 studies should proceed to full text review that was 
resolved through discussion, without the need for independent arbitration. One was excluded as it was 
agreed “bowel rest” (with nasogastric decompression) was not a dietary modification [12], whilst another 
was excluded as the principle endpoint was nutritional status (rather than GI symptoms/signs) [13]. It was 
agreed a 3rd study should proceed to full text review despite doubts regarding whether it would fulfil 
eligibility criteria (inclusion and exclusion) [14]. Of the 5 studies taken forward to full text review, 2 were 
excluded; the first for being a short case series (4 patients) presented in an abbreviated non-original 
research publication [15] and the second for not fulfilling the inclusion criteria (in addition to grounds for 
exclusion based on insufficient reporting of the SSc population) [14]. No studies were excluded due to 
language. An overview of the study selection process is summarised in Figure 1. A summary of the key 
study characteristics and major findings of the 3 remaining studies are presented in Table 1. There was 
full agreement with the risk of bias assessment across all domains for the 3 studies. 
Study characteristics 
Each of the 3 selected studies were published within the last 7 years from centres in the USA (2 studies 
[16, 17]) and France (1 study [18]) respectively. All 3 studies were single centre, small (total of 56 subjects 
with mean 19 per study completing trial), short-term (with an average of 6 weeks) open-label non-
randomised studies (Table 1). The studies applied different inclusion criteria and interventions, precluding 
any formal meta-analysis, as anticipated. Highly selective study eligibility limits the generalizability of each 
of the study findings. Study attrition was reported to be generally low, indicating dietary modifications 
are generally well tolerated in an interventional study setting. 
Interventions  
The three selected studies examined the use of probiotics [16], a low-fermentable oligo-saccharides, 
disaccharides, monosaccharides, and polyol (low FODMAP) diet [18] and a highly individualised medical 
nutrition therapy (MNT) counselling (emphasizing need for increased calorie and protein intake, modified 
textures, and lifestyle modifications) [17].  
Reported outcomes 
Each study utilised validated patient-reported outcome instruments as the primary endpoint for analysis. 
The University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 
questionnaire (UCLA GIT 2.0) was used in 2 studies [16, 17] and the Global Symptomatic Score (GSS) in 
the 3rd [18] (Table 1). There were reported improvements in patient-reported GI symptoms following 
probiotic therapy [16] and adherence to the low-FODMAP diet [18]. MNT counselling improved self-
reported nutritional status but did not improve GI symptoms (or health-related quality of life) [17]. 
Despite the open-label study design, none of the reported studies incorporated objective endpoints (e.g. 
GI physiological studies or imaging) as surrogate markers of GI disease severity.  
Study quality and risk of bias 
A summary of the risk-of-bias assessment of each study is presented in Table 2. Each of the 3 studies were 
felt to have a moderate overall risk of bias. All three studies were considered at high risk of bias for the 
potential impact of confounding variables and blinding; primarily relating to the open-label study design 
and reliance upon PRO instruments as the primary endpoint (Table 2). The eligibility criteria for each study 
may have limited the generalizability of the study findings. For example, the study by Frech et al. required 
moderate-severe distension/bloating scores on baseline SCTC GIT 2.0 questionnaire, as opposed to more 
objective assessment of small intestinal bacterial overgrowth/pseudo-obstruction [16]. Improvements in 
subjective PRO instruments such as the UCLA GIT 2.0 and GSS may have also been influenced by issues 
such as regression to the mean or placebo response. Each of the studies were comparatively small and 
possibly under-powered risking type II error (i.e. missing a clinically meaningful improvement to 
intervention when present).  
Synopsis of excluded studies 
The identification of 5 conference abstracts raises the possibility of publication bias and as the number 
exceeded the number proceeding to full data extraction, we felt it appropriate to offer the findings some 
consideration. Accepting the limitations of conference proceedings, a summary of the interventions and 
reported findings of the 5 potentially eligible studies reported as conference proceedings that were 
identified at study selection is presented in Table 3.  None of the abstracts identified have been published 
subsequently or are related to the published studies that comprise this review. A recent conference 
proceeding is noteworthy as it reports the findings of a comparatively large (n=73) randomised, double 
blind, placebo-controlled trial of probiotic therapy [19]. The study identified significant improvements in 
GI symptoms in both the active treatment arm (as was found in the aforementioned open label study) 
and placebo arm, but changes did not differ between the 2 groups suggesting probiotic therapy may not 
have a role in managing GI symptoms in SSc [16, 19]. The remaining abstracts were smaller, un-blinded or 
open label studies (Table 3). A number of case reports/small case series were excluded from the formal 
data synthesis; some of which may allude to dietary modifications that could be of value in SSc e.g. a case 
series of 4 SSc patients highlighting the potential deleterious effects of a high-fibre diet [15]. A number of 
other ineligible studies raised points of interest, such as the timing of proton pump inhibitor 
administration on gastro-oesophageal reflux symptoms in scleroderma-spectrum disorders [20]. 
Discussion  
To our knowledge, this is the first systematic literature review to address the impact of dietary 
modification on GI symptoms of SSc. At present, we are unable to draw conclusions regarding the efficacy 
of dietary modification in SSc as the evidence-base is limited to a low number of small non-randomised 
uncontrolled open-label trials.  Nonetheless, it has become routine for clinical practice guidelines to make 
recommendations on this subject. This guidance ranges from judicious advice to promote “a mixed 
balanced diet that meets their requirements for both macro and micro nutrients (assuming there are no 
other medical contraindications)” [21] to more specific non evidence-based recommendations advocating 
dietary supplementation with medium-chain triglycerides, the avoidance of lactose or fructose-containing 
foods and encouraging intake of “stool bulking agents (bran and fibres)” [22]. The evidence base for such 
guidance is weak, at time contradictory and could result in an imbalanced diet, nutritional deficiency and, 
possibly, worsened symptoms. For example, the use of high-fibre diets has never been formally studied 
in SSc and the aforementioned small case series suggests it may actually aggravate GI symptoms in SSc 
[15]. Indeed, previous observations indicate dietary intake of food rich in fibre is generally lower in people 
with SSc, which invites speculation as to whether patients encounter aggravation of GI symptoms with 
high-fibre foods [23, 24]. Some clinical practice reviews, meanwhile, specifically advocate the avoidance 
of high fibre foods in SSc patients with GI involvement [7]. Recent work has focussed on the potential 
contribution of the GI microbiota in the pathogenesis of SSc [8]. Whether distinct microbiome signatures 
are the cause or consequence of the disease has yet to be elucidated but this work has resulted in renewed 
interest in dietary modification (including low-FODMAP) and probiotic therapy; both of which could be 
used to modify the GI tract microbiota. The contrasting findings of recent open-label versus randomised 
double-blinded placebo-controlled trials of probiotic therapy highlights the importance of robust trial 
design to provide the evidence-base for future recommendations in this area [16, 19, 25].  
Pragmatic general approaches for the alleviation of symptoms such as elevation of the head of the bed, 
multiple small meals, small bites, cut/chew food well, avoidance of dry food, avoidance of recumbency 
within 3 hours of eating and advice to take plenty of water with solid foods [7, 26]  appear to be, on face 
value, sensible and unlikely to cause physical harm, but could impact on quality of life and social 
participation in other ways. Generic advice of this nature could be amenable to formal testing and the use 
of registries capturing patient-reported outcomes following recommendations to adopt such measures 
could provide much-needed “practice-based evidence” to inform future clinical practice guidelines. 
Conclusions 
At present, the evidence-base around dietary intervention for GI involvement in SSc is very limited and 
future clinical practice guidelines should take a measured approach to such recommendations. Recent 
interest around the potential pathogenic role of the GI microbiome in SSc and the emergence of large 
registries capable of capturing vital practice-based evidence could greatly enhance our understanding of 
both the pathogenesis and specific role of dietary modification in the management of GI involvement in 
SSc.  
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Figure 1. Flow chart summarising study selection process 
Table 1. Summary table of study characteristics and major findings of studies examining the prognostic value of nailfold capillaroscopy in systemic 
sclerosis 
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; low-FODMAP, low-fermentable oligo-saccharides, disaccharides, 
monosaccharides, and polyol; GSS, Global Symptomatic Score; ARA, American Rheumatology Association; GI, gastrointestinal; ES, effect size; UCLA GIT 2.0 questionnaire, 
The University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 questionnaire, lcSSc, limited cutaneous systemic sclerosis; USA, 
United States of America;  * recruitment commenced before the publication of these classification criteria 
Author 
& Date  
Origin Design Descriptio
n 
Study Population Intervention Attrition Eligibility criteria Primary 
outcome  
Adverse 
events 
Reported outcomes 
Frech et 
al. 2011 
[16] 
USA Open-
label 
study 
2-month 
prospectiv
e study of 
probiotic 
therapy 
for GI 
symptoms 
of SSc 
N =10 (8 lcSSc, 9 
female). Mean 
age 51.7 years 
Align 
(bifidobacteri
um infantis) 
or Culturelle 
(lactobacillus) 
taken once a 
day. 
Nil 
reported 
1980 Preliminary 
ARA criteria with 
moderate to 
severe 
distension/bloatin
g scores on SCTC 
GIT 2.0 
questionnaire 
UCLA GIT 
2.0 
questionn
aire (total 
and sub-
scales) 
Diarrhoea 
reported 1 
patient 
(?disease 
or related 
to 
interventi
on) 
Significant improvement in total UCLA GIT 2.0 score 
(mean 0.73 to o.43, P<0.01), reflux scale (mean 0.74 
to 0.64, p<0.05), bloating/distention scale (mean 
2.15 to 0.97, P<0.01) and emotional scales (0.59 to 
0.3, P<0.05) were identified at two months. Largest 
improvement reported for bloating/distention 
(ES=1.76).  
Marie et 
al. 2015 
[18] 
France Open-
label 
study 
1-month 
prospectiv
e study of 
low-
FODMAP 
diet 
Initial cohort of 80 
patients (14 men, 
median age 52.5 
years). 32 SSc 
patients with 
positive fructose 
breath test (40% 
of initial cohort) 
entered study.  
The low-
FODMAP diet 
91% of 
subjects 
were 
compliant 
(55% of 
meals 
adherent 
with low-
FODMAP 
guideline) 
“based on” 2013 
ACR/EULAR 
classification 
criteria*  
The 11-
item GSS 
(GI 
symptoms) 
Nil 
reported 
Despite high rates of severe oesophageal 
dysmotility (60%) and delayed gastric emptying 
(40%) within the study population the median GSS 
at baseline was only 2 (range 0-21).The fructose 
breath test cause GI symptoms in 25/32 patients 
with positive test. Participants with fructose 
malabsorption had higher GSS score at baseline 
than those without (despite lower rates of delayed 
gastric emptying). There was Significant 
improvement in GSS and individual domains 
including nausea, vomiting, abdominal pain, 
bloating, diarrhoea and abdominal tenderness. No 
change in constipation.  
Doerfler 
et al. 
2017 
[17] 
USA Open-
label 
study 
6-week 
tailored 
nutrition 
counsellin
g 
18 (16 female, 
mean age 51 
years) 
Individualised 
medical 
nutrition and 
lifestyle 
counselling. 
Weekly 
phone/email 
contact to 
enhance 
intervention 
adherence.  
4 lost to 
follow up: 
2 required 
PN and/or 
hospitalisa
tion and 2 
lost 
interest in 
study 
Clinician diagnosis 
of SSc referred to 
gastroenterology 
for both GI 
symptoms and 
unintentional 
weight loss 
Primary 
outcome 
was 
nutritional 
status. 
UCLA GIT 
2.0 used as 
secondary 
outcome 
2 subjects 
required 
parenteral 
nutrition 
and/or 
hospitalisa
tion [likely 
disease-
related 
events] 
Significant improvement in abridged patient 
generated subjective global assessment (abPGSGA) 
(13.1 to 7.6, p<0.05) and proportion classified as 
sarcopenic. GI symptoms did not decrease 
significantly (either total GIT 2.0 score or individual 
subscales). There was a statistically insignificant rise 
in calorie intake, BMI, total fat mass, percent 
adiposity, appendicular lean height and total lean 
body mass.   
 Table 2. Risk of bias assessment of studies using the Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS) tool 
 
 
  
Author & 
Year of 
Publicatio
n 
Selection of 
participants 
Confounding 
variables 
Measureme
nt of 
exposure 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Overall risk 
of bias 
Comments 
Frech et 
al. 2011 
[16] 
LOW HIGH UNCERTAIN HIGH LOW LOW MODERATE 
Open label study. The inclusion 
criteria requiring threshold 
patient-reported outcomes 
limits generalizability. The 
improvement may be related to 
regression to mean (as a 
confounding effect). 
Marie et 
al. 2015 
[18] 
LOW HIGH LOW HIGH LOW UNCERTAIN MODERATE 
Open-label study. Selection bias 
with results only applicable to 
SSc patients with objective 
evidence of fructose 
intolerance. The improvement 
may be related to regression to 
mean (as a confounding effect). 
Doerfler 
et al. 
2017 
[17] 
LOW HIGH HIGH HIGH HIGH LOW MODERATE 
Open-label study. Small study 
with high drop out. Highly 
selective inclusion criteria. The 
improvement may be related to 
regression to mean (as a 
confounding effect). 
 Table 3. Summary of the interventions and reported findings of conference abstracts reporting effects of dietary modification in systemic sclerosis[25] 
Authors Conference Intervention Study design Reported outcome 
Garcia-
Collinot et al. 
2018 [25] 
PANLAR 
Congress 
2018 
Probiotic fungus and 
antibiotic therapy for 
bacterial overgrowth in 
SSc 
40 SSc patients assigned 
to 3 groups: probiotic, 
antibiotic or both 
All 3 interventions helped with symptoms of bacterial 
overgrowth but combination of probiotic and 
antibiotic appeared most effective with fewer 
adverse events 
Marighela et 
al. 2017[19] 
ACR Annual 
Meeting 
2017 
Probiotic therapy 8-week double-blind, 
placebo-controlled RCT 
(n=73) 
No difference in GI symptoms between groups at 8 
weeks but alteration in circulating T-cell populations. 
Luchetti et al. 
2016 [27] 
EULAR 
Congress 
2016 
Mediterranean diet 
with low introduction 
of meat and dairy 
products 
6-month open label study 
in 38 patients with SSc 
and GI involvement 
“Patients reported a consistent improvement in GI 
symptoms and quality of life” 
Malgorzewicz 
et al. 2015 
[28] 
ESPEN 
Congress 
2015 
Supplementary 
Resource Protein 
3 month open label study 
of supplementary protein 
in malnourished patients 
with SSc (n=10) 
Improvement in appetite (and nutritional status) 
observed at 3 months  
Gullen-del 
Castillo et al. 
2013 [29] 
ACR Annual 
Meeting 
2013  
Adherence to gluten-
free diet in patients 
with SSc and coeliac 
disease 
Identified 4 patients with 
SSc and GI symptoms who 
had concomitant coeliac 
disease 
Improvement in small bowel symptoms (diarrhoea, 
abdominal distension/bloating and weight loss) in all 
patients following institution of gluten-free diet 
(sustained remission in 50% of patients)  
 
 
PANLAR, Pan-American League of Rheumatology Associations; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; ESPEN, European 
Society for Clinical Nutrition and Metabolism; SSc, systemic sclerosis; RCT, randomised controlled trial; GI, gastrointestinal 
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Supplementary Online Appendix 1: Study Selection criteria for Dietary Modification in SSc SLR 
 
Inclusion Criteria Assessment 
Studies must satisfy the following criteria: 
 Studies reporting an assessment of the efficacy/impact 
of dietary modification of any description on GI 
manifestations in patients with SSc 
 Longitudinal study reporting with at least 2 assessments 
(baseline and following intervention)   
 
 If fulfils both 
inclusion criteria 
X  if does not fulfil both 
inclusion criteria 
 
 
 
 
Exclusion Criteria Corresponding Letter 
Pre-Clinical/Animal studies A 
Studies of childhood or juvenile SSc B 
Studies including patients with mixed 
connective tissue disease, undifferentiated 
connective tissue disease or overlap 
syndromes, where an SSc cohort is not 
described and reported separately  
C 
Studies designed to develop or validate 
measurement scales 
D 
Case reports E 
Qualitative research F 
Non-original research publications (i.e. 
editorials or reviews) 
G 
Abbreviated reports (i.e. letters to editors) H 
Conference abstracts I 
Non-English language J 
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Supplementary Online Appendix 2: data extraction form 
Systematic review of dietary modification in SSc: Data Extraction Form  
Data extraction form 
Citation   
 
Retrieval information (date/location)  
 
 
Eligibility criteria 
 
Study Details  
 
Comments 
 
 
JP 
LS 
Studies reporting an assessment of the efficacy/impact of dietary modification 
of any description in patients with SSc  
Longitudinal study reporting with at least 2 assessments (baseline and following 
intervention)  
Doesn’t fulfil exclusion criteria 
Tick if 
correct and 
proceed: 
Year of publication   
Diagnostic criteria used    
Study design  
Format of Intervention   
Study setting / country   
Sample characteristics  
 (incl. size & subgroup) 
 
Gender  
Age  
Active treatment Interventions   
Control intervention   
Duration of study   
Primary end-points  
Secondary end-points  
Primary Outcomes:  
Adverse events  
Withdrawal  
Secondary Outcomes:  
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Supplementary Online Appendix 3: Risk of bias tools used 
 
1. Cochrane Risk of Bias Assessment Tool for Randomised Trials 
 
Study Validity Domains Assessment Comments 
1. Sequence Generation: Was the allocation sequence 
adequately controlled? 
Yes  
No 
Unclear 
 
2. Allocation concealment: Was the sequence 
generation adequately concealed before group 
assignments? 
Yes 
No 
Unclear 
 
3. Blinding of participants and personnel: Was 
knowledge of the allocated interventions adequately 
hidden from the participants and personnel after the 
participants were assigned to respective groups? 
Yes 
No 
Unclear 
 
4. Blinding of outcome assessors: Was knowledge of the 
allocated interventions adequately hidden from the 
outcome assessors after participants were assigned 
to respective groups 
Yes 
No 
Unclear 
 
5. Incomplete outcome data: Were incomplete 
outcome data adequately addressed? 
Yes 
No 
Unclear 
 
6. Selective outcome reporting: Are reports of the study 
free of suggestion of selective outcome reporting? 
Yes 
No 
Unclear 
 
7. Other sources of bias: Was the study apparently free 
of other problems that could put it at a risk of bias? 
Yes 
No 
Unclear 
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2. The risk-of-bias assessment tool for nonrandomized studies (RoBANS)  
 
Domain Details Risk of bias  Comments 
Selection of 
participants 
Selection bias caused by the 
inadequate selection of participants 
Low 
High 
Unclear 
 
Confounding 
variables 
Selection bias caused by the 
inadequate confirmation and 
consideration of 
confounding variable 
 
Low 
High 
Unclear 
 
Measurement of 
exposure 
Performance bias caused by the 
inadequate measurement of 
exposure 
Low 
High 
Unclear 
 
Blinding of outcome 
assessments 
Detection bias caused by the 
inadequate blinding of outcome 
assessments 
Low 
High 
Unclear 
 
Incomplete outcome 
data 
Attrition bias caused by the 
inadequate handling of incomplete 
outcome data 
Low 
High 
Unclear 
 
Selective outcome 
reporting 
Reporting bias caused by the 
selective reporting of outcomes 
Low 
High 
Unclear 
 
Overall risk of bias  Low 
Mod 
High 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
